Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.

Jones SC, Budnitz DS, Sorbello A, Mehta H.

Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1099-106. doi: 10.1002/pds.3499. Epub 2013 Aug 20.

2.

Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.

Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS.

Clin Infect Dis. 2013 Oct;57(7):971-80. doi: 10.1093/cid/cit439. Epub 2013 Aug 14.

PMID:
23948133
3.

Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.

Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL.

Am J Health Syst Pharm. 2014 Jan 1;71(1):37-43. doi: 10.2146/ajhp130165.

PMID:
24352180
4.

Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation.

Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G.

Drug Saf. 2007;30(8):705-13.

PMID:
17696583
5.

Emergency department visits for antibiotic-associated adverse events.

Shehab N, Patel PR, Srinivasan A, Budnitz DS.

Clin Infect Dis. 2008 Sep 15;47(6):735-43. doi: 10.1086/591126.

PMID:
18694344
6.

Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature.

Chang B, Knowles SR, Weber E.

Ann Pharmacother. 2010 Apr;44(4):740-5. doi: 10.1345/aph.1M579. Epub 2010 Mar 16.

PMID:
20233910
7.

Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.

Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.

J Antimicrob Chemother. 2009 May;63(5):886-94. doi: 10.1093/jac/dkp057. Epub 2009 Mar 11.

PMID:
19279051
8.

Glucose homeostasis abnormalities associated with use of gatifloxacin.

Frothingham R.

Clin Infect Dis. 2005 Nov 1;41(9):1269-76. Epub 2005 Sep 28.

PMID:
16206101
9.

Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study.

Paterson JM, Mamdani MM, Manno M, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network.

CMAJ. 2012 Oct 2;184(14):1565-70. doi: 10.1503/cmaj.111823. Epub 2012 Aug 13.

10.

US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014.

Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS.

JAMA. 2016 Nov 22;316(20):2115-2125. doi: 10.1001/jama.2016.16201.

PMID:
27893129
11.

[Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].

Wang SH, Xie YC, Jiang B, Zhang JY, Qu Y, Zhao Y, Li Y, Qiao SS, Xu CL.

Zhonghua Yi Xue Za Zhi. 2013 May 7;93(17):1283-6. Chinese.

PMID:
24029473
12.

Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.

Walbrown MA, Aspinall SL, Bayliss NK, Stone RA, Cunningham F, Squier CL, Good CB.

J Manag Care Pharm. 2008 Jan-Feb;14(1):34-40.

13.

Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.

Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA.

Clin Infect Dis. 2015 Feb 15;60(4):566-77. doi: 10.1093/cid/ciu914. Epub 2014 Nov 18.

PMID:
25409476
14.

The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.

Iannini PB.

Curr Med Res Opin. 2007 Jun;23(6):1403-13. Epub 2007 May 8. Review. Erratum in: Curr Med Res Opin. 2007 Sep;23(9):2303. Dosage error in article text.

PMID:
17559736
15.

Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.

Szałek E, Karbownik A, Grabowski T, Sobańska K, Wolc A, Grześkowiak E.

Pharmacol Rep. 2013;65(5):1383-90.

16.
17.

Arrhythmias associated with fluoroquinolone therapy.

Falagas ME, Rafailidis PI, Rosmarakis ES.

Int J Antimicrob Agents. 2007 Apr;29(4):374-9. Epub 2007 Jan 22. Review.

PMID:
17241772
18.

Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.

Gavin JR 3rd, Kubin R, Choudhri S, Kubitza D, Himmel H, Gross R, Meyer JM.

Drug Saf. 2004;27(9):671-86.

PMID:
15230648
19.

Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.

Phillips ST, Nagaro K, Sambol SP, Johnson S, Gerding DN.

Anaerobe. 2011 Aug;17(4):166-9. doi: 10.1016/j.anaerobe.2011.03.015. Epub 2011 Apr 14.

PMID:
21511046
20.

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.

Dalhoff A, Schubert S.

Int J Antimicrob Agents. 2010 Sep;36(3):216-21. doi: 10.1016/j.ijantimicag.2010.04.014. Epub 2010 Jul 14.

PMID:
20630710

Supplemental Content

Support Center